Psychopharmacology

, Volume 107, Issue 4, pp 503–510 | Cite as

Early dyskinesia — vulnerability

  • Jonathan O. Cole
  • George Gardos
  • Lenore A. Boling
  • David Marby
  • David Haskell
  • Patricia Moore
Original Investigations

Abstract

Relative vulnerability to dyskinesia in terms of exposure to antipsychotic drugs prior to onset of dyskinesia was studied in a sample of 100 psychiatric patients with dyskinesia onset generally within a year or less of the point of study entry. Unipolar and bipolar patients were more vulnerable to dyskinesia than other diagnostic groups. In the total sample, lithium exposure did not appear to delay development of dyskinesia. Longer exposure to antiparkinson drugs was associated with delayed onset of dyskinesia. Past exposure to electroconvulsive therapy was related to decreased vulnerability to dyskinesia.

Key words

Tardive dyskinesia Antipsychotic drugs Schizophrenia Depression Bipolar disorder 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Casey DE (1984) Tardive dyskinesia and affective disorders. In: Gardos G, Casey DE (eds) Tardive dyskinesia and affective disorder. American Psychiatric Press, Washington, DC, pp 1–20Google Scholar
  2. Gardos G, Cole JO (1983) Tardive dyskinesia and anticholinergic drugs. Am J Psychiatry 140:200–202Google Scholar
  3. Gardos G, Cole JO, Rapkin R, LaBrie R, Bacquelod E, Moore P, Sovner R, Doyle J (1984) Anticholinergic challenge and neuroleptic withdrawal. Arch Gen Psychiatry 41:1030–1035Google Scholar
  4. Gardos G, Cole JO, Haskell D, Marby DW, Paine-Schniebolk S, Moore P (1988) The natural hystory of tardive dyskinesia. J Clin Psychopharmacology 8[4] suppl:31–37Google Scholar
  5. Guy W (1976) ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education and Welfare, Washington, DC, pp 534–537Google Scholar
  6. Jeste DV, Wyatt RJ (1982) Understanding and treating tardive dyskinesia. Gulford Press, New YorkGoogle Scholar
  7. Kane JM, Smith JM (1982) Tardive dyskinesia. Arch Gen Psychiatry 39:473–481Google Scholar
  8. Kane J, Woerner M, Weinhold P et al. (1982) A prospective study of tardive dyskinesia development: preliminary results. J Clin Psychopharmacol 2:345–349Google Scholar
  9. Kane JM, Woerner M, Borenstein M, Wegner J, Lieberman J (1986) Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 22:254–258Google Scholar
  10. Klawans H, Weiner W, Nauseida P (1977) The effect of lithium on an animal model of tardive dyskinesia. Prog Neuropsychopharmacol 1:53–60Google Scholar
  11. Mason AS, Granacher RP (1978) Clnical handbook of antipsychotic drug therapy. Brunner/Mazel, New YorkGoogle Scholar
  12. Schooler NR, Kane JM (1982) Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 39:486–487Google Scholar
  13. Simpson G, Varga E, Lee H, Zoubok B (1978) Tardive dyskinesia and psychotropic drug history. Psychopharmacology 58:117–124Google Scholar
  14. Toenniessen L, Casey D, McFarland B (1985) Tardive dyskinesia in the aged: duration of treatment relationships. Arch Gen Psychiatry 42:278–284Google Scholar
  15. Yassa R, Ghadrian A, Schwartz G (1983) Prevalence of tardive dyskinesia in affective disorder patients. J Clin Psychiatry 44:410–412Google Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • Jonathan O. Cole
    • 1
  • George Gardos
    • 1
  • Lenore A. Boling
    • 1
  • David Marby
    • 1
  • David Haskell
    • 2
  • Patricia Moore
    • 2
  1. 1.McLean HospitalBelmontUSA
  2. 2.Boston VA Medical ClinicBostonUSA

Personalised recommendations